---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-22-000003"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T07:03:03.183869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships

## Summary
- FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.
- Cash and restricted cash $580.4M at Dec 31, 2021, no debt; raised $175M in equity in 2021.
- Received $80M BMS option for PRX005, $60M Roche milestone for prasinezumab, $60M upfront from Novo Nordisk for ATTR.
- Reached SPA agreement with FDA for confirmatory Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis; Phase 1 of PRX005 initiated.
- 2022 guidance: net cash used $120-132M; expected net loss $154-170M; ending cash ~$454M.

## SEC filing metadata
- accession: 0001559053-22-000003
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/0001559053-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/prta-20220217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-22-000003
- JSON: https://secwatch.observer/filing/0001559053-22-000003.json
- Plain text: https://secwatch.observer/filing/0001559053-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.